The Patient Experience of Gene Therapy for Hemophilia: Qualitative Interviews with Trial Patients

por Miesbach, Wolfgang, Klamroth, Robert
Publicado 2020

Long-term efficacy and safety of a pasteurized, plasma-derived factor VIII concentrate (Beriate(®) P) in patients with haemophilia A

por Klamroth, Robert, Gottstein, Saskia, Orlovic, Marija, Heinrichs, Christl
Publicado 2014

P1633: OUTCOME OF SURGICAL INTERVENTIONS IN PATIENTS WITH HAEMOPHILIA A AND B TREATED WITH EXTENDED HALF-LIFE (EHL) FACTOR CONCENTRATES IN A SINGLE CENTRE

por Vaide, Ines, Gottstein, Saskia, Kubicek, Cornelia, Orlovich, Maria, Klamroth, Robert
Publicado 2023

Illustrative Cases from the Pathfinder Clinical Trials of Patients with Hemophilia A Treated with Turoctocog Alfa Pegol (N8-GP)

por Klamroth, Robert, Hampton, Kingsley, Saulyte Trakymienė, Sonata, Korsholm, Lars, Carcao, Manuel
Publicado 2021

Medikamentöse Thrombose-Prophylaxe bei ambulanten COVID-19-Patienten

por Darius, Harald, Grothues, Jens, Haas, Sylvia, Heinemann, Markus, Klamroth, Robert, Miesbach, Wolfgang
Publicado 2021

Efficacy of rFIXFc versus rIX-FP for the Treatment of Patients with Hemophilia B: Matching-Adjusted Indirect Comparison of B-LONG and PROLONG-9FP Trials

por Astermark, Jan, Wojciechowski, Piotr, Aballéa, Samuel, Hakimi, Zalmai, Nazir, Jameel, Klamroth, Robert
Publicado 2021

Efficacy of rFIXFc versus N9-GP Prophylaxis in Patients with Hemophilia B: Matching-Adjusted Indirect Comparison of B-LONG and PARADIGM 2 Trials

por Mancuso, Maria Elisa, Eriksson, Daniel, Falk, Aletta, Hakimi, Zalmai, Wojciechowski, Piotr, Wdowiak, Marlena, Klamroth, Robert
Publicado 2023

Pharmacokinetics, immunogenicity, safety, and preliminary efficacy of subcutaneous turoctocog alfa pegol in previously treated patients with severe hemophilia A (alleviate 1)

por Klamroth, Robert, Feistritzer, Clemens, Friedrich, Ute, Lentz, Steven R., Reichwald, Kirsten, Zak, Marek, Chowdary, Pratima
Publicado 2019

Design of a Real-World Observational Study in Previously Untreated and Minimally Treated Hemophilia A Patients: Protect-NOW

por Oldenburg, Johannes, Halimeh, Susan, Hall, Georgina W., Klamroth, Robert, Vera, Pascual Marco, Jansen, Martina, Mathias, Mary
Publicado 2023

Population Pharmacokinetic Modeling Of On-Demand And Surgical Use Of Nonacog Beta Pegol (N9-GP) And rFIXFc Based Upon The paradigm 7 Comparative Pharmacokinetic Study

por Simpson, Mindy L, Kulkarni, Roshni, Escuriola Ettingshausen, Carmen, Medom Meldgaard, Rikke, Cooper, David L, Klamroth, Robert
Publicado 2019

Indirect Treatment Comparison of Damoctocog Alfa Pegol versus Turoctocog Alfa Pegol as Prophylactic Treatment in Patients with Hemophilia A

por Vashi, Parth, Batt, Katharine, Klamroth, Robert, Mancuso, Maria Elisa, Majewska, Renata, Tiede, Andreas, Mantovani, Lorenzo Giovanni
Publicado 2021

Factor VIII activity and bleeding risk during prophylaxis for severe hemophilia A: a population pharmacokinetic model

por Tiede, Andreas, Karim, Faraizah Abdul, Jiménez-Yuste, Victor, Klamroth, Robert, Lejniece, Sandra, Suzuki, Takashi, Groth, Andreas, Santagostino, Elena
Publicado 2020

Matching-adjusted indirect comparisons of annualized bleeding rate and utilization of BAY 94-9027 versus three recombinant factor VIII agents for prophylaxis in patients with sever...

por Batt, Katharine, Gao, Wei, Ayyagari, Rajeev, Deschaseaux, Céline, Vashi, Parth B, Yao, Zhiwen, Wang, Yao, Kessabi, Sophia, Klamroth, Robert
Publicado 2019

Turoctocog alfa pegol (N8‐GP) in severe hemophilia A: Long‐term safety and efficacy in previously treated patients of all ages in the pathfinder8 study

por Lentz, Steven R., Kavakli, Kaan, Klamroth, Robert, Misgav, Mudi, Nagao, Azusa, Tosetto, Alberto, Jørgensen, Pernille Juul, Zak, Marek, Nemes, Laszlo
Publicado 2022

Targeting an elevated FVIII level using personalized rurioctocog alfa pegol prophylaxis in specific patient populations with hemophilia A: post hoc subanalysis of the randomized, p...

por Escuriola-Ettingshausen, Carmen, Klamroth, Robert, Escobar, Miguel, Stasyshyn, Oleksandra, Tangada, Srilatha, Engl, Werner, Honauer, Ivan, Lee, Hye-Youn, Chowdary, Pratima, Windyga, Jerzy
Publicado 2023

Efficacy of rFVIIIFc versus Emicizumab for the Treatment of Patients with Hemophilia A without Inhibitors: Matching-Adjusted Indirect Comparison of A-LONG and HAVEN Trials

por Klamroth, Robert, Wojciechowski, Piotr, Aballéa, Samuel, Diamand, Françoise, Hakimi, Zalmai, Nazir, Jameel, Abad-Franch, Lydia, Lethagen, Stefan, Santagostino, Elena, Tarantino, Michael D
Publicado 2021

Efficacy and safety of damoctocog alfa pegol prophylaxis in patients ⩾40 years with severe haemophilia A and comorbidities: post hoc analysis from the PROTECT VIII study

por Reding, Mark T., Pabinger, Ingrid, Holme, Pål Andrè, Maas Enriquez, Monika, Mancuso, Maria Elisa, Lalezari, Shadan, Miesbach, Wolfgang, Di Minno, Giovanni, Klamroth, Robert, Hermans, Cedric
Publicado 2023

Health-Related Quality of Life in Children and Adolescents with Hereditary Bleeding Disorders and in Children and Adolescents with Stroke: Cross-Sectional Comparison to Siblings an...

por Neuner, Bruno, von Mackensen, Sylvia, Holzhauer, Susanne, Funk, Stephanie, Klamroth, Robert, Kurnik, Karin, Krümpel, Anne, Halimeh, Susan, Reinke, Sarah, Frühwald, Michael, Nowak-Göttl, Ulrike
Publicado 2016

Favorable pharmacokinetics in hemophilia B for nonacog beta pegol versus recombinant factor IX‐Fc fusion protein: A randomized trial

por Escuriola Ettingshausen, Carmen, Hegemann, Inga, Simpson, Mindy L., Cuker, Adam, Kulkarni, Roshni, Pruthi, Rajiv K., Garly, May‐Lill, Meldgaard, Rikke M., Persson, Paula, Klamroth, Robert
Publicado 2019

Efficacy and safety of simoctocog alfa (Nuwiq®) in patients with severe hemophilia A: a review of clinical trial data from the GENA program

por Lissitchkov, Toshko, Klukowska, Anna, Pasi, John, Kessler, Craig M., Klamroth, Robert, Liesner, Raina J., Belyanskaya, Larisa, Walter, Olaf, Knaub, Sigurd, Bichler, Johann, Jansen, Martina, Oldenburg, Johannes
Publicado 2019